All Stories

  1. Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers

    Article • British Journal of Clinical Pharmacology, February 2016, Wiley

    Dr Allison M Kitten

  2. Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir

    Article • Clinical Pharmacology in Drug Development, January 2016, Wiley

    Dr Allison M Kitten

  3. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors

    Article • Clinical Infectious Diseases, January 2016, Oxford University Press (OUP)

    Dr Allison M Kitten

  4. Reply to “Pharmacokinetics in hepatic impairment: Mind the protein binding”

    Article • Journal of Hepatology, December 2015, Elsevier

    Dr Allison M Kitten

  5. Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir

    Article • Antimicrobial Agents and Chemotherapy, November 2015, ASM Journals

    Dr Allison M Kitten

  6. Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies

    Article • The AAPS Journal, November 2015, American Association of Pharmaceutical Scientists (AAPS)

    Dr Allison M Kitten

  7. No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects

    Article • Antimicrobial Agents and Chemotherapy, November 2015, ASM Journals

    Dr Allison M Kitten

  8. Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects

    Article • Clinical Therapeutics, November 2015, Elsevier

    Dr Allison M Kitten

  9. Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir

    Article • Antimicrobial Agents and Chemotherapy, October 2015, ASM Journals

    Dr Allison M Kitten

  10. Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects

    Article • Journal of Viral Hepatitis, October 2015, Wiley

    Dr Allison M Kitten

  11. Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment

    Article • Journal of Hepatology, October 2015, Elsevier

    Dr Allison M Kitten, Professor Eric J Lawitz

  12. Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

    Article • Clinical Pharmacokinetics, September 2015, Springer Science + Business Media

    Dr Allison M Kitten

  13. Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials

    Article • Clinical Pharmacokinetics, August 2015, Springer Science + Business Media

    Dr Allison M Kitten

  14. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir

    Article • Journal of Hepatology, July 2015, Elsevier

    Dr Allison M Kitten

  15. Small-molecule compounds exhibiting target-mediated drug disposition - A case example of ABT-384

    Article • The Journal of Clinical Pharmacology, June 2015, Wiley

    Dr Allison M Kitten

  16. FRI0156 Pharmacokinetics of ABT-122, A Dual TNF- and IL-17A-Targeted DVD-IG™, After Single Dosing in Healthy Volunteers and Multiple Dosing in Subjects with Rheumatoid Arthritis

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    Dr Allison M Kitten

  17. Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety

    Article • Clinical Pharmacokinetics, April 2015, Springer Science + Business Media

    Dr Allison M Kitten

  18. P0823 : Pharmacokinetics of paritaprevir, ombitasvir, ritonavir and ribavirin in subjects with HCV genotype 4 infection

    Article • Journal of Hepatology, April 2015, Elsevier

    Dr Allison M Kitten

  19. P0905 : No significant interaction among ombitasvir/paritaprevir/ritonavir +/− dasabuvir and sofosbuvir

    Article • Journal of Hepatology, April 2015, Elsevier

    Dr Allison M Kitten

  20. P0820 : Pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in subjects with HCV genotype 1 infection in phase 3 studies

    Article • Journal of Hepatology, April 2015, Elsevier

    Dr Allison M Kitten

  21. Sa1265 Adalimumab Serum Concentration As a Predictor for Clinical Efficacy in Ulcerative Colitis

    Article • Gastroenterology, April 2015, Elsevier

    Dr Allison M Kitten

  22. Pharmacokinetics and Exposure–Efficacy Relationship of Adalimumab in Pediatric Patients with Moderate to Severe Crohnʼs Disease

    Article • Inflammatory Bowel Diseases, April 2015, Wolters Kluwer Health

    Dr Allison M Kitten

  23. A Semi-Mechanistic Integrated Pharmacokinetic/Pharmacodynamic Model of the Testosterone Effects of the Gonadotropin-Releasing Hormone Agonist Leuprolide in Prostate Cancer Patients

    Article • Clinical Pharmacokinetics, March 2015, Springer Science + Business Media

    Dr Allison M Kitten

  24. Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT‐450, Ombitasvir, and Dasabuvir

    Article • American Journal of Transplantation, February 2015, Wiley

    Dr Allison M Kitten

  25. Erratum to: Population Pharmacokinetics and Exposure-Uric Acid Analyses After Single and Multiple Doses of ABT-639, a Calcium Channel Blocker, in Healthy Volunteers

    Article • The AAPS Journal, February 2015, American Association of Pharmaceutical Scientists (AAPS)

    Dr Allison M Kitten

  26. Population Pharmacokinetics and Exposure-Uric Acid Analyses After Single and Multiple Doses of ABT-639, a Calcium Channel Blocker, in Healthy Volunteers

    Article • The AAPS Journal, January 2015, American Association of Pharmaceutical Scientists (AAPS)

    Dr Allison M Kitten

  27. A novel ritonavir paediatric powder formulation is bioequivalent to ritonavir oral solution with a similar food effect

    Article • Antiviral Therapy, January 2015, International Medical Press

    Dr Allison M Kitten

  28. Pharmacokinetics of hydrocodone/acetaminophen combination product in children ages 6-17 with moderate to moderately severe postoperative pain

    Article • The Journal of Clinical Pharmacology, September 2014, Wiley

    Dr Allison M Kitten

  29. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration

    Article • Clinical Pharmacokinetics, September 2014, Springer Science + Business Media

    Dr Allison M Kitten

  30. Population pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers following single and multiple dose regimens

    Article • Biopharmaceutics & Drug Disposition, August 2014, Wiley

    Dr Allison M Kitten

  31. A phase 1 study to evaluate effect of food on veliparib pharmacokinetics and relative bioavailability in subjects with solid tumors

    Article • Cancer Chemotherapy and Pharmacology, July 2014, Springer Science + Business Media

    Dr Allison M Kitten

  32. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia

    Article • Cancer Chemotherapy and Pharmacology, July 2014, Springer Science + Business Media

    Dr Allison M Kitten

  33. Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL, in patients with cancer

    Article • Journal of Clinical Pharmacy and Therapeutics, July 2014, Wiley

    Dr Allison M Kitten

  34. Population pharmacokinetics of levodopa in subjects with advanced P arkinson's disease: levodopa‐carbidopa intestinal gel infusion vs . oral tablets

    Article • British Journal of Clinical Pharmacology, June 2014, Wiley

    Dr Allison M Kitten

  35. The H3antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers

    Article • British Journal of Clinical Pharmacology, May 2014, Wiley

    Dr Allison M Kitten

  36. Evaluation of the pharmacokinetics and pharmacodynamics of two leuprolide acetate 45 mg 6-month depot formulations in patients with prostate cancer

    Article • Clinical Pharmacology in Drug Development, May 2014, Wiley

    Dr Allison M Kitten

  37. Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanib

    Article • Cancer Chemotherapy and Pharmacology, May 2014, Springer Science + Business Media

    Dr Allison M Kitten

  38. Pharmacokinetic and Exposure–Response Analyses of Leuprolide Following Administration of Leuprolide Acetate 3-Month Depot Formulations to Children with Central Precocious Puberty

    Article • Clinical Drug Investigation, April 2014, Springer Science + Business Media

    Dr Allison M Kitten

  39. Population Pharmacokinetic Modeling of Veliparib (ABT-888) in Patients with Non-Hematologic Malignancies

    Article • Clinical Pharmacokinetics, January 2014, Springer Science + Business Media

    Dr Allison M Kitten

  40. Pooled Population Pharmacokinetic Analysis of Phase I, II and III Studies of Linifanib in Cancer Patients

    Article • Clinical Pharmacokinetics, December 2013, Springer Science + Business Media

    Dr Allison M Kitten

  41. Three monthly doses of palivizumab are not adequate for 5-month protection: A population pharmacokinetic analysis

    Article • Pulmonary Pharmacology & Therapeutics, December 2013, Elsevier

    Dr Allison M Kitten

  42. Exposure-Response (Safety) Analysis to Identify Linifanib Dose for a Phase III Study in Patients With Hepatocellular Carcinoma

    Article • Clinical Therapeutics, November 2013, Elsevier

    Dr Allison M Kitten

  43. A food effect study and dose proportionality study to assess the pharmacokinetics and safety of bardoxolone methyl in healthy volunteers

    Article • Clinical Pharmacology in Drug Development, October 2013, Wiley

    Dr Allison M Kitten

  44. Sa1204 Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

    Article • Gastroenterology, May 2013, Elsevier

    Dr Allison M Kitten

  45. Sa1195 Exposure-Efficacy Relationship (ER) for Adalimumab During Induction Phase of Treatment of Adult Patients With Moderate to Severe Ulcerative Colitis

    Article • Gastroenterology, May 2013, Elsevier

    Dr Allison M Kitten

  46. Safety, tolerability and pharmacokinetics of the histamine H3receptor antagonist, ABT-288, in healthy young adults and elderly volunteers

    Article • British Journal of Clinical Pharmacology, April 2013, Wiley

    Dr Allison M Kitten

  47. Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/ pharmacodynamic analysis of three phase 1 trials

    Article • British Journal of Clinical Pharmacology, March 2013, Wiley

    Dr Allison M Kitten

  48. Clinical Safety, Pharmacokinetics, and Pharmacodynamics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT-384 in Healthy Volunteers and Elderly Adults

    Article • Clinical Pharmacology in Drug Development, February 2013, Wiley

    Dr Allison M Kitten

  49. Effect of Ketoconazole on the Pharmacokinetics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT-384 and Its Two Active Metabolites in Healthy Volunteers: Population Analysis of Data from a Drug-Drug Interaction Study

    Article • Drug Metabolism and Disposition, February 2013, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Allison M Kitten

  50. Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients

    Article • The AAPS Journal, December 2012, American Association of Pharmaceutical Scientists (AAPS)

    Dr Allison M Kitten

  51. Exposure-Clinical Response Analysis of Paricalcitol in Patients With Chronic Kidney Disease (Stage 5) on Hemodialysis or Peritoneal Dialysis

    Article • The Journal of Clinical Pharmacology, August 2012, Wiley

    Dr Allison M Kitten

  52. Pharmacokinetics and Safety of the Lopinavir/Ritonavir Tablet 500/125 mg Twice Daily Coadministered With Efavirenz in Healthy Adult Participants

    Article • The Journal of Clinical Pharmacology, August 2012, Wiley

    Dr Allison M Kitten

  53. Pharmacokinetics of the TRPV1 Antagonist ABT-102 in Healthy Human Volunteers: Population Analysis of Data From 3 Phase 1 Trials

    Article • The Journal of Clinical Pharmacology, July 2012, Wiley

    Dr Allison M Kitten

  54. Population Analyses of Efficacy and Safety of ABT-594 in Subjects with Diabetic Peripheral Neuropathic Pain

    Article • The AAPS Journal, February 2012, American Association of Pharmaceutical Scientists (AAPS)

    Dr Allison M Kitten

  55. Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature

    Article • Journal of Vascular Surgery, February 2012, Elsevier

    Dr Allison M Kitten

  56. A Phase 1 Study to Evaluate the Bioavailability and Food Effect of 2 Solid-Dispersion Formulations of the TRPV1 Antagonist ABT-102, Relative to the Oral Solution Formulation, in Healthy Human Volunteers

    Article • Clinical Pharmacology in Drug Development, January 2012, Wiley

    Dr Allison M Kitten

  57. Population pharmacokinetics of ABT-594 in subjects with diabetic peripheral neuropathic pain

    Article • Journal of Clinical Pharmacy and Therapeutics, December 2011, Wiley

    Dr Allison M Kitten

  58. Abstract 1300: Evaluating the relative bioavailability of a new formulation of navitoclax (ABT-263) in both cancer patients and healthy volunteers

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr Allison M Kitten

  59. Abstract 1277: Modeling the correlation of linifanib (ABT-869) pharmacokinetic (PK) exposure and DCE-MRI response in patients with advanced or metastatic solid tumors

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr Allison M Kitten

  60. Single- and Multiple-Dose Pharmacokinetics, Safety, and Tolerability of the Selective α7 Neuronal Nicotinic Receptor Agonist, ABT-107, in Healthy Human Volunteers

    Article • The Journal of Clinical Pharmacology, April 2011, Wiley

    Dr Allison M Kitten

  61. 907 Pharmacokinetic Analysis Supports a Five Monthly Dose Schedule for Palivizumab

    Article • Pediatric Research, November 2010, Nature

    Dr Allison M Kitten

  62. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors

    Article • Cancer Chemotherapy and Pharmacology, January 2010, Springer Science + Business Media

    Dr Allison M Kitten

  63. Abstract C126: Exposure-response (E-R) relationship in ABT-263-induced thrombocytopenia and the effect of platelet transfusion in dogs

    Article • Molecular Cancer Therapeutics, December 2009, American Association for Cancer Research (AACR)

    Dr Allison M Kitten

  64. Abstract B216: Exposure-response (E-R) relationship of ABT-263-induced thrombocytopenia in cancer patients in phase 1 studies

    Article • Molecular Cancer Therapeutics, December 2009, American Association for Cancer Research (AACR)

    Dr Allison M Kitten

  65. Abstract B53: Assessment of the effect of food on the oral bioavailability and assessment of diurnal variation in the pharmacokinetics of linifanib

    Article • Molecular Cancer Therapeutics, December 2009, American Association for Cancer Research (AACR)

    Dr Allison M Kitten

  66. Effects of Acid-Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir-Boosted Atazanavir

    Article • The Journal of Clinical Pharmacology, May 2008, Wiley

    Dr Allison M Kitten

  67. 381 PHARMACOKINETICS OF 12-HOUR CONTROLLED-RELEASE HYDROCODONE AND ACETAMINOPHEN TABLETS IN HEALTHY SUBJECTS FOLLOWING SINGLE- AND MULTIPLE DOSE(S)

    Article • Osteoarthritis and Cartilage, December 2007, Elsevier

    Dr Allison M Kitten

  68. Corrigendum: Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate

    Article • The AAPS Journal, September 2007, American Association of Pharmaceutical Scientists (AAPS)

    Dr Allison M Kitten

  69. Levosimendan, Compared to Placebo, Provides Rapid, Consistent, and Sustained Symptomatic Improvement: REVIVE II

    Article • Journal of Cardiac Failure, August 2007, Elsevier

    Dr Allison M Kitten

  70. Effect of the Rate of Niacin Administration on the Plasma and Urine Pharmacokinetics of Niacin and Its Metabolites

    Article • The Journal of Clinical Pharmacology, June 2007, Wiley

    Dr Allison M Kitten

  71. Population pharmacokinetics of S(−)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate

    Article • The AAPS Journal, June 2007, American Association of Pharmaceutical Scientists (AAPS)

    Dr Allison M Kitten

  72. Lack of Effect of Gastric Acid-Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir in HIV-Infected Patients

    Article • AIDS Patient Care and STDs, April 2007, Mary Ann Liebert Inc

    Dr Allison M Kitten

  73. The Tablet Formulation of Lopinavir/Ritonavir Provides Similar Bioavailability to the Soft-Gelatin Capsule Formulation With Less Pharmacokinetic Variability and Diminished Food Effect

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, April 2007, Wolters Kluwer Health

    Dr Allison M Kitten

  74. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States

    Article • Epilepsy Research, March 2007, Elsevier

    Dr Allison M Kitten

  75. Does It Really Matter When a Blood Sample for Valproic Acid Concentration is Taken Following Once-Daily Administration of Divalproex-ER?

    Article • Therapeutic Drug Monitoring, June 2006, Wolters Kluwer Health

    Dr Allison M Kitten

  76. Predicted plasma valproic acid concentrations in patients missing and replacing a full daily dose of extended-release divalproex sodium

    Article • American Journal of Health-System Pharmacy, May 2006, American Society of Health System Pharmacists

    Dr Allison M Kitten

  77. PIII-58Distinct absorption characteristics of five oral formulations of valproic acid

    Article • Clinical Pharmacology & Therapeutics, February 2006, Nature

    Dr Allison M Kitten

  78. PI-78Modelling the drug interaction of lopinavir/ritonavir with efavirenz

    Article • Clinical Pharmacology & Therapeutics, February 2006, Nature

    Dr Allison M Kitten

  79. Population pharmacokinetics (P?PK) of valproic acid (VPA) following rapid infusion in epilepsy patients

    Article • Clinical Pharmacology & Therapeutics, February 2004, Nature

    Dr Allison M Kitten

  80. Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients

    Article • Antimicrobial Agents and Chemotherapy, January 2003, ASM Journals

    Dr Allison M Kitten

  81. Endothelin-1 expression in long-term cultures of fetal rat calvarial osteoblasts: Regulation by BMP-7

    Article • Journal of Cellular Physiology, January 2001, Wiley

    Dr Allison M Kitten

  82. Expression of osteogenic protein-1 mRNA in cultured kidney cells

    Article • Journal of Cellular Physiology, December 1999, Wiley

    Dr Allison M Kitten